Celularity Inc. /
Sequence LifeScience, Inc.
Celularity adds Rebound product through Sequence asset purchase




What happened
Celularity Inc. acquired certain assets from Sequence LifeScience, Inc., including Rebound, a full thickness placental-derived allograft matrix product. The transaction closed on Oct. 9, 2024.
The aggregate consideration was $5,500,000, including an upfront cash payment, monthly milestone payments, and a credit for a previous payment.
The source
Everything on this page comes from the source below.
Celularity adds Rebound product through Sequence asset purchase
This document is the source for the companies, stage and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly